Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Stomatitis 4Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Pancreatic Neoplasms 1Oral Ulcer 1Esophagitis 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × avasopasem manganese × Clear all
NCT03689712 2023-10-24

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Galera Therapeutics, Inc.

Phase 3 Completed
455 enrolled 11 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Stomatitis, Oral Ulcer

NCT04529850 2022-08-16

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Galera Therapeutics, Inc.

Phase 2 Completed
38 enrolled 10 charts
Head & Neck

Head and Neck Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡